Lung Cancer Screening Expands with New Guidelines, But Gaps Remain
Lung cancer screening has increased overall, but significant disparities remain, particularly among rural and underserved populations.
Category: Lung Cancer
Lung Cancer
Latest
Lung Cancer
Latest
Nanowire-Based Urine Test with AI Detects Early-Stage Lung Cancer with High Accuracy
Researchers developed a non-invasive cancer detection tool using nanowire-based miRNA extraction and AI to identify lung cancer in urine.
Lung Cancer
Latest
PathAI Adds MET Predict to AISight for NSCLC Assessments
The MET Predict assists in identifying NSCLC tumors with MET exon 14 skipping or MET amplification directly from H&E whole slide images.
DELFI Diagnostics’ Blood Test Validated for Early Lung Cancer Detection
DELFI’s blood-based Lung test has been clinically validated to enhance early detection of lung cancer, demonstrating high sensitivity.
Read More
PROphet Platform’s Predictive Ability to be Demonstrated
OncoHost will highlight the PROphet platform’s capability to predict benefits from therapies across various cancers.
Read More
DELFI Collaborates with Hospital System to Improve Lung Cancer Screening
OSF HealthCare will use DELFI’s FirstLook Lung blood test to enhance lung cancer screening rates and early detection efforts.
Read More
CAP Publishes Guideline for PD-L1 Testing of Lung Cancer Patients
CAP developed recommendations for testing immunotherapy biomarkers, such as PD-L1 and TM), in patients with NSCLC.
Read More
Nucleix’s New Assay May Differentiate Small Cell Lung Cancer Subtypes
Nucleix will present data that demonstrates the potential of a PCR assay to accurately differentiate between small cell lung cancer subtypes.Â
Read More
Study Demonstrates Clinical Validity of OncoHost’s NSCLC Test
The test guides first-line treatment selection by identifying individuals with the highest likelihood of benefit from PD-1/PD-L1 inhibitors
Read More
Noninvasive Testing Key to Id’ing Lung Cancer
New noninvasive diagnostic solutions for lung cancer being developed function as a complement to LDCT imaging.
Read More
New Epigenomic Technology Platform Predicts Immunotherapy Response in NSCLC Patients
The epigenomic technology platform predicts and monitors immunotherapy responses for patients with non-small cell lung cancer (NSCLC).
Read More
New ChromaCode Collaboration to Improve NSCLC Biomarker Testing Access
ChromaCode will collaborate with Tennessee Oncology to test the performance of ChromaCode’s HDPCR NSCLC biomarker assay.Â
Read More
New Sensor Technology May Enable Early Lung Cancer Detection
The diagnostic, which requires only a simple urine test to read the results, could make lung cancer screening more accessible worldwide.
Read More
Freenome Initiates Clinical Study of Blood Test for Early Lung Cancer Screening
Freenome’s PROACT LUNG study is intended to validate the clinical performance of its blood test for lung cancer screening.Â
Read More
DELFI Diagnostics Supports Legislation for CMS to Review New Lung Cancer Liquid Biopsies
DELFI Diagnostics is supporting the recently introduced Lung Cancer Screening and Prevention Act (H.R. 6693).
Read More
Liquid Biopsy Predicts Immunotherapy Response, Toxicity in Advanced Lung Cancer Patients
Liquid biopsies could predict which lung cancer patients are responding to immunotherapies or may develop immune-related side effects.
Read More
Veracyte’s Nasal Swab Test Gets Clinical Validation for Lung Cancer Risk Assessment
Clinical validation data shows that Veracyte’s Percepta Nasal Swab test determines lung cancer risk with high accuracy for certain patients.
Read More
OncoHost Develops Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients
OncoHost developed a novel computational model for predicting significant immune-related adverse events in NSCLC patients.
Read More